CLYM: SEC Form 8-K filed by Climb Bio Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for CLYM
Across the 27 sessions after earlier CLYM headlines, the stock closed higher 15 times and lower 10 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CLYM | SPY |
|---|---|---|---|
| Oct 26, 2026 | Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026and 1 other headline that session | -13.5% | +0.7% |
| Oct 20, 2026 | Deutsche Bank initiated coverage on Climb Bio with a new price target | +11.0% | +0.3% |
| Oct 2, 2026 | Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug | -1.2% | +0.7% |
| Sep 3, 2026 | Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy | -3.1% | +1.0% |
| Sep 2, 2026 | Climb Bio to Present at Upcoming Investor Conferences | +1.6% | +0.4% |
| Aug 6, 2026 | Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates | +12.3% | -0.2% |
Quantisnow market dataNASDAQ
CLYM
Climb Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for CLYM
Full CLYM profile on Quantisnow Follow CLYM and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time